EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials

Milton Packer iD, Mardi Gomberg-Maitland iD, Ryan J Tedford iD, David Langleben iD, Jean-Luc Vachiery, Barry A Borlaug iD

Circulation · 2026

DOI: 10.1161/circulationaha.126.081957 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation, 2026. Verfasst von Milton Packer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Baylor Heart and Vascular Institute, Dallas, TX and Imperial College, London, UK (M.P.). Hauptthemen laut MEDLINE: Activin Receptors, Type II, Signal Transduction, Heart Failure, Hypertension, Pulmonary. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The totality of evidence indicates that the mechanisms underlying the increase in pulmonary vascular resistance in patients with combined postcapillary and precapillary pulmonary hypertension (CpcPH) associated with heart failure with preserved ejection fraction (HFpEF) differ meaningfully from those responsible for the increase in pulmonary vascular resistance in patients with pulmonary arterial hypertension. CpcPH-HFpEF is a complex disorder involving the pulmonary veins, left atrium, and pulmonary arterioles, but recent evidence has highlighted a potentially central role for pulmonary venous and left atrial (LA) dysfunction. Epicardial adipose tissue occupies anatomical proximity to both structures, allowing derivative secretory products to influence their structure and function. The most well-characterized proinflammatory adipokine released from an expanded epicardial fat mass is activin A, which causes fibrosis and cardiomyocyte stiffness and senescence in underlying tissues by signaling through activin type II receptor signal transduction. Such signaling regulates pulmonary venular responses to mechanical stretch, and circulating activin A is elevated in patients with HFpEF who have enlarged LA chambers, pulmonary venous hypertension and increased pulmonary vascular resistance. The adipokine hypothesis of HFpEF identified activin A and activin type II receptor signaling as key adipokine mediators in the pathogenesis of HFpEF. Experimentally, activin A signaling promotes the development of both atrial myopathy and HFpEF, and activin type II receptor ligand traps alleviate HFpEF and ameliorate both the pulmonary vascular and left heart abnormalities in experimental models in which CpcPH-HFpEF is induced by obesity. These collective observations led to the prospective hypothesis that adipokine modulation by sotatercept would mediate benefits on the left heart in patients with CpcPH-HFpEF. These expectations were validated when the CADENCE trial showed that sotatercept decreased both pulmonary artery wedge pressures and left atrial volume index in patients with CpcPH-HFpEF, which are effects that could not explained by a decrease in pulmonary vascular resistance. Activin A released from an expanded epicardial adipose tissue promotes both pulmonary venous and left atrial remodeling and fibrosis in vivo, which (in turn) are effects that can be attenuated by an activin A decoy. The efficacy of sotatercept to slow the progression of CpcPH-HFpEF is now being tested in a phase III outcomes trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activin Receptors, Type IISignal TransductionHeart FailureHypertension, PulmonaryStroke VolumeHumansAnimalsActivinsClinical Trials as TopicVascular ResistanceEpicardial Adipose Tissue

Stichwörter der Autor:innen

activin Aadipokineheart failure with preserved ejection fractionsotatercept

Substanzen

Activin Receptors, Type IIActivinsactivin A

Autor:innen und Institutionen

  • Baylor Heart and Vascular Institute, Dallas, TX and Imperial College, London, UK (M.P.).
  • Department of Medicine, Section of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (M.G.-M.).
  • Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC (R.J.T.).
  • Department of Medicine, Section of Cardiology, Center for Pulmonary Vascular Disease, Azrieli Heart Center, Jewish General Hospital, McGill University, Montreal, Canada (D.L.).
  • Department of Cardiology, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium (J.-L.V.).
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).

ORCID-Profile: Milton Packer, Mardi Gomberg-Maitland, Ryan J Tedford, David Langleben, Barry A Borlaug

Förderung

  • NCRR NIH HHS

Zitieren

APA

Packer, M., Gomberg-Maitland, M., Tedford, R. J., Langleben, D., Vachiery, J. L., & Borlaug, B. A. (2026). Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials. Circulation. https://doi.org/10.1161/circulationaha.126.081957

Vancouver

Packer M, Gomberg-Maitland M, Tedford RJ, Langleben D, Vachiery JL, Borlaug BA. Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials. Circulation. 2026. doi:10.1161/circulationaha.126.081957

BibTeX
@article{Packer2026,
  author = {Packer, Milton and Gomberg-Maitland, Mardi and Tedford, Ryan J and Langleben, David and Vachiery, Jean-Luc and Borlaug, Barry A},
  title = {Effect of Activin Type II Receptor Signaling in Patients With HFpEF and Pulmonary Hypertension: A Critical Analysis of Biological Mechanisms and Clinical Trials},
  journal = {Circulation},
  year = {2026},
  doi = {10.1161/circulationaha.126.081957}
}
Kostenlos starten →